Viking Therapeutics, Inc.

VKTX

$34.39

+1.21%

2026-09-04 10:35:18 EDT+$0.41

Healthcare

Biotechnology

NASDAQ

Active Trading

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The ...

Price Action of VKTX

$34.39

+1.21%+$0.41

High—

Low—

52W High-20.3%

Rel. vol—

Interval

Range65m

Volume—SMA5SMA10

—

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 by Brian Lian, Ph.D., who serves as President and CEO, the company is headquartered in San Diego, California. Viking's pipeline is primarily focused on ...Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 by Brian Lian, Ph.D., who serves as President and CEO, the company is headquartered in San Diego, California. Viking's pipeline is primarily focused on metabolic diseases, with a strong emphasis on obesity and related conditions. The company's lead product candidate, VK2809, is an orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). It is currently in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Another candidate, VK5211, is an oral, non-steroidal selective androgen receptor modulator (SARM) undergoing Phase II studies for patients recovering from hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials, and VK0214, another TRβ agonist, is being developed for X-linked adrenoleukodystrophy (X-ALD). As a clinical-stage company, Viking has no approved products or revenue, and its financials reflect significant investment in research and development. The company's market capitalization is approximately $4 billion, and it maintains a strong cash position to fund its clinical programs. Key financial metrics include a current ratio of 4.72, indicating ample liquidity, and negative operating cash flow typical for biotech firms in the development stage. The company employs around 53 people, with a lean team of experts in drug development, finance, and commercialization. Viking's scientific approach is centered on targeting nuclear hormone receptors to modulate gene expression with high specificity, aiming to improve efficacy and safety profiles. The company has generated significant interest in the obesity space, with its pipeline potentially offering alternatives to existing GLP-1 therapies. Viking's leadership team, led by Dr. Lian, brings over two decades of experience in biotechnology, and the company is committed to advancing treatments that can make a meaningful difference in patients' lives. With a robust pipeline and a clear focus, Viking Therapeutics is positioned to become a key player in the metabolic disease market.ExpandCollapse

Founded

2012

Employees

CEO

Brian Lian

Full Name

Viking Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-94.56%

Market Cap

$4.01B

Current Ratio

4.72

WACC

7.75%

ROIC

-129.83%

Contact Information

https://www.vikingtherapeutics.com

858 704 4660

9920 Pacific Heights Boulevard, San Diego, CA 92121

Key Metrics of VKTX

Snapshot

Latest / TTM · 6 periods

Market Cap

$4.01B

ROCE

-135.8%

EV / EBITDA

-7.19x

-74.3% YoY

FCF Yield

-10.6%

-3.5% YoY

Cash Conversion Cycle

-121102.8d

Current Ratio

4.72

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of VKTX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-7.29x

n/a

Debt / Equity

0.01

n/a

Current Ratio

4.72

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of VKTX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-1.07 · Revenue $0.00 · 12 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-1.10 · Revenue $0.00 · 12 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-4.61 · Revenue $7.17M · 14 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-1.01 · Revenue $0.00 · 5 analysts

Recent history

Jul 29, 2026
Q2 FY2026 · Results reported
EPS $-1.10 · Revenue $0.00
View filing
Apr 30, 2026
Q1 FY2026 · Results reported
EPS $-1.37 · Revenue $0.00
View filing
Feb 11, 2026
FY2025 · Annual results
EPS $-3.19 · Revenue $0.00
View filing
Oct 23, 2025
Q3 FY2025 · Results reported
EPS $-0.81 · Revenue $0.00
View filing
Jul 23, 2025
Q2 FY2025 · Results reported
EPS $-0.58 · Revenue $0.00
View filing
Apr 24, 2025
Q1 FY2025 · Results reported
EPS $-0.41 · Revenue $0.00
View filing

Financial Statements of VKTX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-359.6M	-227.1%	+19.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-278.7M	-217.4%	-9.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	-83.1%	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	9.33x	-71.8%	-17.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$715.7M	-21.2%	-14.2%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-3.19 vs -2.72	-17.2%	-1.10 vs -1.07	-3.0%
Revenue Surprise	$0 vs $1.5M	-100.0%	—	—

Insider Transactions of VKTX

Acquisitions (A)

Since Jun 1, 2026

Disposals (D)

Since Jun 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 1, 2026	Kelly-Gemmell Dorothy Elizabeth	director	Stock Option (Right to Buy)	A	40,800	$31.74
Aug 1, 2026	Kelly-Gemmell Dorothy Elizabeth	director	Common Stock, par value $0.00001 per share	A	6,333	—
Aug 1, 2026	Kelly-Gemmell Dorothy Elizabeth	—	—	—	0	—
Jul 29, 2026	Lian Brian	director, officer: President & CEO	Common Stock, par value $0.00001 per share	D	148,517	$33.32
Jul 29, 2026	ZANTE GREG	officer: Chief Financial Officer	Common Stock, par value $0.00001 per share	D	21,217	$33.47

Earnings Call Transcript of VKTX

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and welcome to the Viking Therapeutics Second Quarter 2026 Financial Results Conference Call. And as a reminder, this conference call is being recorded today, July 29, 2026. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie. Stephanie Diaz Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 29, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments. Brian Lian: Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the second quarter and 6 months ended June 30, 2026, and review recent updates across our pipeline programs and organization. During the second quarter, we continued to advance each of the programs within our expanding obesity franchise. With respect to our lead compound, VK2735, a dual agonist of the GLP-1 and GIP receptors, Viking's Phase III VANQUISH clinical program continued on track. The VANQUISH program includes 2 studies: VANQUISH-1 evaluating the treatment of adults with obesity and VANQUISH-2 evaluating the treatment of adults with obesity and type 2 diabetes. Both trials are fully enrolled and during the second quarter, both proceeded to advance according to plan. Also during the second quarter, the company continued preparing for the initiation of a Phase III program to evaluate the oral tablet formulation of VK2735. This program will consist of 2 studies and will generally mirror the VANQUISH Phase III program for the subcutaneous formulation. During the second quarter, our team continued to make progress toward initiation of these important studies, which are expected to begin in the fourth quarter of this year. During the second quarter, Viking also continued to execute its novel maintenance dosing study of VK2735. This range-finding study is designed to explore a variety of dosing regimens to identify suitable doses for further evaluation. The maintenance study leverages VK2735's unique in …

Leadership Team of VKTX

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Brian Lian	President, Chief Executive Officer & Director	USD 1,045,000	—	1966	Active
Marianne Mancini	Chief Operating Officer	USD 765,000	Female	1965	Active
Gregory S. Zante	Chief Financial Officer	USD 738,000	Male	1971	Active
Michael Morneau	Vice President of Finance & Administration	USD 375,333	Male	1965	Active
Katherine Mercier	Vice President of Quality and Compliance	—	Female	—	Active
Hubert C. Chen	Chief Medical Officer	—	—	1969	Active
Neil Aubuchon	Chief Commercial Officer	—	Male	1970	Active
Geoffrey E. Barker	Chief Development Officer	—	—	—	Active
Nils U. Olsson	Senior Vice President of Technical Operations	—	—	—	Active
Kenneth Herman	Senior Vice President of Commercial, Marketing & Sales	—	Male	—	Active

Recent News of VKTX

Zacks Investment Research8/17/2026Neutral

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

Fool - Investing News8/16/2026Neutral

2 GLP-1 Stocks That Could Double Your Money by 2031

They are fairly risky, but their potential upside is massive.

The Motley Fool8/8/2026Neutral

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

Defense World8/8/2026Neutral

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 18.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 542,516 shares of the biotechnology company's stock after buying an additional 82,941 shares during the period. Dimensional Fund

Seeking Alpha8/7/2026Neutral

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.

Historical Employee Count of VKTX

Current

Change

+47.22%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	53	10-K	Feb 11, 2026	View
Dec 31, 2024	36	10-K	Feb 26, 2025	View
Dec 31, 2023	27	10-K	Feb 7, 2024	View
Dec 31, 2022	21	10-K	Feb 10, 2023	View
Dec 31, 2021	17	10-K	Feb 9, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Viking Therapeutics, Inc.